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The first Registry Review focused on data and results from analysis of arthroplasty registers, in this, 
the second Registry Review, we have expanded the remit to include non-arthroplasty registries. This 
month, we also feature the recently published protocol of a randomised controlled trial nested within 
an arthroplasty registry, an important study design that is likely to form an important efficient study 
methodology in registry research. The most notable recent development for academics working with 
arthroplasty registry data, however, is a simple change in nomenclature. From August 2020, what was 
previously known as the National Joint Registry for England, Wales, Northern Ireland and the Isle of 
Man has been officially renamed the “National Joint Registry” a change that will lead editors and 
authors alike to breath a collective sigh of relief over word counts, particularly in titles and abstracts. 
Non-arthroplasty 
August 2020 saw the publication of the first article arising from the UK Non-Arthroplasty Hip 
Registry (NAHR) which looked at periacetabular osteotomy (PAO) for developmental dysplasia of 
the hip and femoroacetabular impingement (FAI).1 In this study, published in JBJS Am, the authors 
identified 630 PAOs performed between January 2012 and February 2019 and then reported EQ-5D 
and iHOT-12 scores pre-operatively and at six months, 12 months and two years post-operatively. 
This retrospective observational study included all patients undergoing a single stage PAO within the 
period specified, if performed for DDH or FAI secondary to acetabular retroversion and with a Tonnis 
grade of 0 or 1. Eleven surgeons contributed data to the analyses with three surgeons contributing 
90% of all cases. Overall, 87.5% of patients were available for follow-up at six months with 74.3% 
available at 12 months and 55.4% at two years with a slightly higher proportion of patients in the FAI 
group being available at longer follow-up points. The minimum important difference in iHOT-12 
score was set at ≥ 9 points and this improvement was achieved in both DDH and FAI groups by 
77.9% and 76.9% of patients not lost to follow up after six months. These results led the authors to 
conclude that PAO is an effective surgical treatment for patients with symptomatic DDH of FAI due 
to acetabular retroversion. The loss to follow-up and limited number of surgeons contributing to this 
study are clear weaknesses, however it does represent the early years of data collection and we expect 
that as the database matures, more surgeons will contribute making future findings more 
generalisable. As lessons are learnt regarding data collection the loss to follow up with hopefully 
reduce. The authors commendably performed sensitivity analyses to investigate whether those 
patients lost to follow up were more likely to have been unhappy, but it is still possible that patients 
with poor outcomes withdrew for that reason. This study is limited by the same weaknesses of all 
registry analysis in that it is not possible to draw causal inference but only suggest association 
between exposure and outcome. In addition, it is not clear what proportion of contributing surgeon’s 
cases were entered into the register, so may be subject to selection bias. In our opinion, the 
conclusions seem valid in that most patients that were selected for surgery, entered onto the register 
and not lost to follow up appeared to show improvements in EQ-5D and iHOT-12 above the 
minimally important clinical difference. We also feel that this is an important article for those 
surgeons interested in non-arthroplasty hip surgery and is a success of the registry and those that have 
worked hard to set it up. 
 
Hip 
One of the most important articles to be released in recent months is the protocol for a randomised 
controlled trial nested within the Dutch Arthroplasty Registry.2 In this study the authors aim to 
investigate the effectiveness of dual mobility cups compared with uni-polar cups for preventing 
dislocation after primary hip arthroplasty in elderly patients. The population for this study will be 
patients over 70 years of age undergoing total hip replacement (THR) using the posterior approach 
and a cup size that allows a 32 or 36mm femoral head. The study uses dislocation by three months, 
one year and two years as its primary outcome with PROs evaluated at the same time points. The 
exclusion criteria do cause some concern given patients with “epilepsy, spasticity, dementia, mental 
retardation, or alcoholism” to be excluded, a cohort generally considered by many to be at high risk of 
dislocation and therefore a population where dual-mobility cups are often considered. It may also be 
relevant that the power calculation for this study was based on articles that included these “high risk” 
patients and therefore may be at risk of a smaller effect size that previously reported and as such be 
underpowered. The limitation on femoral head size also limits how many patients can be recruited; 
having reviewed the Dutch registry report we estimate that 10-15% of patients would not be eligible 
based on head size alone, which may cause issues with recruitment and generalisability. The nested 
design of this study means that long after the two year follow-up period ends the cohort can be 
monitored for the outcomes of revision and mortality, a concept that increases the efficiency of the 
study and allows for long term reporting without the need to maintain contact with patients 
individually. Putting the above concerns aside, this is an impressive and important study and one 
which we eagerly await the results of. 
 
In August 2020, Blom et al. published their analysis of over 700,000 elective THRs in the NJR in 
which they sought to compare different approaches to the hip.3 The population was patients 
undergoing primary THR with osteoarthritis (OA) as an indication and the comparator or reference 
group was those THRs where a conventional posterior approach was used. The outcomes of interest 
were revision, short term mortality and PROMS including EQ-5D and Oxford Hip Score. In models 
adjusted for age, sex, additional indications (as well as OA), ASA, fixation, year of primary and head 
size the authors observed an association between the use of a conventional lateral, minimally invasive 
lateral, minimally invasive anterior and trans-trochanteric approaches and increased hazard of 
revision. When BMI was also added in as a co-variate the association only remained for the 
conventional lateral approach. There were no clinically relevant differences in PROMs between the 
different approaches, but the conventional lateral approach was associated with a higher risk of 90-
day mortality (HR 1.15 95% CI 1.01, 1.3). This study, the largest of its type looking at approaches in 
THR supports the continued use of the conventional posterior approach and suggests that large, well 
designed studies will be needed to assess any potential benefit from either minimally invasive 
posterior or conventional anterior approach. 
 
Knee 
January 2020 saw the publication of a comparison of conventional polyethylene and highly cross-
linked polyethylene (HXLPE) in primary total knee replacement (TKR) in the JBJS by Partridge et 
al.4 The authors analysed data recorded in the NJR of 550,658 TKRs implanted between 2003 and 
2014 to principally compare rates of aseptic revision. The analyses focus on a within brand 
comparison of three commonly used TKR prostheses (Nexgen, PFC Sigma and Triathlon) to account 
for the fact that implant brands may demonstrate differing survival results. In the comparison of TKRs 
with conventional polyethylene and those using HXLPE there was no observed difference in the 
overall hazard of revision for any of the three chosen TKR prostheses. The authors note that the use of 
(the more expensive) HXLPE is increasing in the NJR and conclude that this study suggests there is 
no survival benefit in using HXLPE up to 12 years. Sub-group analyses of patients under 60 years of 
age and those with a BMI >35kg/m2 who had a Triathlon TKR did suggest some overall survival 
benefit in the use of HXLPE which leads the authors to conclude that further work is needed to assess 
the potential benefit of using HXLPE in these cohorts. The study is prone to selection bias, given that 
patients were selected for the implant rather than randomised and as the study is observational, we can 
only discuss the association of polyethylene type and survival and not draw conclusions that any 
difference in survival is caused by the type of polyethylene used. Most importantly however, given 
the high survival expected of TKRs in the long-term, greater follow-up may be required to 
demonstrate any difference between the groups analysed in this study. 
 
In an interesting study published in Acta Orthopaedica, El-Galaly et al. analysed the Danish Knee 
Arthroplasty Registry to investigate the survival of TKR following either High Tibial Osteotomy 
(HTO) or medial unicompartmental knee replacement (UKR).5 The authors included 978 TKR 
following UKR and 1,155 following HTO and used revision for any cause as their outcome. Analyses 
adjusted using a propensity score matching technique, showed a 2.7 times increased hazard of 
revision of TKRs for any cause following UKR compared to HTO (HR 2.7 95% CI 2.4, 3.1). Given 
the relatively low numbers included in this study, it is prone to residual confounding and there may 
also be some issues with completeness of reporting of which TKRs had previously had a HTO as 
these data were not available within the registry unlike the UKR group. Whilst interesting, the 
premise of this study is to aid decision making for patients who are eligible for both UKR and HTO. 
This may be a somewhat limited group, but this study does provide useful information to both patients 
and surgeons. The authors conclude that UKR “should be considered a definitive treatment in line 
with TKA rather than a temporary treatment to postpone TKA”, a sentiment that we agree with. 
 
Shoulder 
August saw the publication of our own meta-analysis written in collaboration between the 
Universities of Exeter Oxford and Bristol and published in The Lancet Rheumatology. In this study 
we reviewed the survival of shoulder replacements past 10 years in both case-series and registries.6 
The pooled ten year survival of both total anatomic shoulder replacement and hemi-arthroplasty was 
over 90% when data were extracted from case-series. Only one registry (the Australian Orthopaedic 
Association National Joint Replacement Register (AONJRR)) contributed data and when weighted by 
construct, the pooled 10 year survival of anatomic total shoulder replacement was 92.0% (95% CI 
91.0, 93.0) and 85.5% (95% CI 83.3, 87.7) for humeral hemi-arthroplasty. Reverse total shoulder 
replacement was stratified by indication, with those performed for osteoarthritis demonstrating a 
94.4% (95% CI 93.4, 95.7) 10-year survival and those performed for rotator cuff arthropathy 93.6% 
(95% CI 91.1, 95.8)). These results are reassuring for patients and surgeons alike, however they need 
to be interpreted with caution as the fact a joint replacement has not been revised does not necessarily 
mean it is a success if there is not a viable revision option. The study did however go on to review the 
Patient Reported Outcomes (PROs) reported in case-series and showed a substantial and sustained 
improvement from baseline scores at 10 years. One of the key findings of this study, however, was the 
paucity of long-term survival results reporting results stratified by construct and published in 
registries. Reporting by construct is key given the fact different implant designs can be expected to 
demonstrate different survival results when used in combination, in a similar way to what has been 
previously observed in hip and knee replacement.7,8 In view of this we encourage registries to report 
survival by construct. The reporting of PROs was also limited in registries. Only the New Zealand 
registry reported PROs by construct, but with no baseline scores to compare to, interpretation of this 
data is challenging. The reporting of PROs by registries, particularly for shoulder replacement, is 
important and we hope will become more commonplace in the future. 
Conclusion 
2020 continued to be an interesting year for registry research with articles published in a variety of 
general interest journals as well as traditional orthopaedic ones. We eagerly await more research from 
the impressive Non-Arthroplasty Hip Registry as well as other registries such as the Bone and Joint 
Infection Registry as their data mature. 
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